PPT-CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

IntroductionOverview Lowering HbA1c Reduces the Risk of Microvascular Complications But What About Macrovascular Complications December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM . Client ID DP ID Bank Name Branch Name Address Bank Account No Account type Please tick the proper box SB Current Other Please specify 9 Digit Code Number of the Bank and Branch as appearing on the MICR Cheque issued by the Bank Please attach a and the Labor Market: Evidence from the Massachusetts Reform. Jonathan T. Kolstad. Wharton . School, University of Pennsylvania and NBER. Amanda E. Kowalski . Department . of Economics, Yale and NBER. Pharmacology 49.222. Bill Diehl-Jones RN, PhD. Faculty of Nursing and Department of Zoology. Agenda. A Zen Review. Overview of CNS and ANS. Neurotransmitters and 2. nd. Messengers. Cholinergic Agonists and Antagonists. Add on to insulin. EFFICACY AND TOLERABILITY. OF GLP-1 RECEPTOR AGONISTS. AND DPP-4 INHIBITORS AS ADDON THERAPY TO INSULIN . Complementing Insulin Therapy to Achieve Glycemic. Control. Anthony H. Barnett . and Glycemic Treatment Options. Rocky . Mountain/ACP. Internal . Medicine Conference. Banff. , AB. November 22, 2012. David C.W. Lau, MD, PhD, FRCPC. Depts. of Medicine. , . Biochem. . . & . Molec. Aspirin in Primary Prevention, GLP-1 Agonists, Metformin, Psychotropic Drug Monitoring. Nathan Bertsch, PharmD. Mitchell Elting, MD. Most patients should not take aspirin for primary prevention of cardiovascular disease. Insulin and Incretins: the perfect Partnership? Stephen Colagiuri, MD Professor of Metabolic Health Boden Institute of Obesity, Nutrition and Exercise University of Sydney Sydney, Australia Moderator Birnhack. Commentary by Lionel . Bently. General. Mandate Palestine ‘1917-1948’. Balfour Declaration (1917). League of Nations Mandate 1922: home for Jewish people/to facilitate self-government. Governed by High Commissioner (initially Herbert Samuel) with an Advisory Council . Oral hypoglycemics. Factors to consider:. Cost. Availability. Side effects. Tolerability. Risk. Accessory benefits. metformin. Metformin is the . preferred initial pharmacologic agent . for the treatment of type 2 diabetes. . David J Albrecht D.O.. Heart & Vascular 2018 Winter Conference. Cardiovascular risk . m. odification in relation to current diabetes management . therapies. Case study highlighting the therapeutic decisions . Part I. F. . Hosseinpanah. Obesity Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University. of Medical Sciences. November 23, 2014. The incretin effect. Up to 70% of post-glucose insulin secretion is due to the effects of incretins. November 2016. Andrew Gallagher. Consultant Physician. and Endocrinologist. NHS Greater Glasgow & Clyde. Prevalence – 2015 data. WORLDWIDE. . Almost 300 million people with diabetes aged 20-79. Diabetes Management . for the Cardiologist. Confidential. Do Not Distribute. 1. To understand the physiologic relationships between cardiovascular disease (CVD) and Type 2 Diabetes Mellitus (DM), and review the statistics behind the risk. for People With HIV. Suman Srinivasa, MD, MS. Massachusetts General Hospital. Harvard Medical School. Boston, MA. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years.